You are here

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Aortic ulceration in a tocilizumab-treated patient with Takayasu arteritis’ by Liebling et al
Free
  1. Yoshikazu Nakaoka
  1. Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan
  1. Correspondence to Yoshikazu Nakaoka, Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan; ynakaoka{at}ncvc.go.jp

https://doi.org/10.1136/annrheumdis-2018-214239

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I thank Liebling and colleagues for their interest in our manuscript1 and for sharing their experience with a patient with refractory Takayasu arteritis who developed aortic ulceration while on tocilizumab therapy.2 Our first multicentre, randomised, double-blind, placebo-controlled study (the TAKT study) showed a favourable effect for tocilizumab over placebo in patients with refractory Takayasu arteritis. As shown in online supplementary figure S1 of our manuscript,1 the study included patients who did not respond to conventional or biologic disease-modifying antirheumatic drugs, similar to the patient reported by Liebling et al. The data from an open-label extension of this study, the largest …

    View Full Text

    Linked Articles